Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thyroid hormone receptor-associated protein 3 (THRAP3) is a nuclear protein that functions in pre-mRNA splicing and remains associated with spliced mRNA, likely interacting with the exon junction complex[1][3][4]. It acts as a transcription coactivator, notably enhancing the activity of the CLOCK-BMAL1 heterodimer on circadian gene targets, and participates in the positive regulation of the circadian clock[1][6]. THRAP3 is implicated in the stability of specific mRNAs, regulation of gene expression, alternative splicing, response to DNA damage, and mRNA decay[1][3][4]. It is not considered a classical drug target such as a receptor or an enzyme, but alterations in its function have been associated with certain cancers, including soft tissue sarcoma and telangiectatic osteogenic sarcoma[1]. Common alternative names and aliases include TRAP150 and BCLAF2[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thyroid hormone receptor-associated protein 3 (THRAP3).